DOC (ASX) Ann: AGM Chair and CEO Addresses

Originally posted by rustys33: ↑

Didnt like - my jpegs - take 2

It appears things are on track. Its good to see the continued increase in consultations along with supply constraints being effectively addressed.

1) Minimum growth of 40% in demand for consultations . Consultation volumes: we believe that there is unmet demand for our service given its popularity, so we are confident that as we increase the supply of consultations, we will see growth in demand to match it. YTD at the end of February, consultation volumes were in line with our plan.
2) Continued stability of our technology platform Pleasingly during this period we have had no major downtime that has significantly affected client service and we have been above our required Service Level throughout the period. As for SLA service credits, we are discussing with AXA the refinement of our SLAs so that they are focused on the most important measures: clinical safety, patient experience, and commercial outcomes.
3) The launch of the Mixed Clinical Workforce proposition in Q2 2023 The launch of Mixed Clinical Workforce: preparation is in hand, and we are working through the patient pathway so that patients are guided to the most appropriate clinician for their situation. This is an important change for our partners and corporate clients as well, so there is an extensive engagement with them so that they and their employees are ready to use the new service. We will need to roll out the new model at a pace that fits with their requirements.
4) Being able to recruit and retain enough clinicians to meet patient demand and tightly manage incentive payments Recruitment of clinicians: we have started the recruitment of Advanced Nurse Practitioners, and this is generally on track. We have to manage the fine balance of recruiting ANPs in time to onboard and train them for the launch of Mixed Clinical Workforce, but not so early that they are sitting on the bench waiting to be utilised.
5) Being able to drive productivity gains and no material unanticipated increases in non-operating costs Operational efficiency: we have already taken the opportunity to streamline our triage processes, and we have started the work to look at our Patient Experience processes, in preparation for change later in H2. We have also identified opportunities to contain non-operating costs, offsetting slightly higher technology spend in these early months of the year as we work through the important tech deliveries that support Mixed Clinical Workforce and our partners’ own product launches.
6) Being able to implement inflation-adjusted price increases pursuant to our agreement with AXA On price increases, we are working through the calculation of price increases that respond to inflation in our clinician costs, for agreement with AXA over the coming weeks.
7) Drawdown of Tranches 2 and 3 of the AXA loan facility in 2023On funding: we have already drawn down the 2nd Tranche of the AXA loan, taking the total drawdown to £7.5m in total, with the final tranche expected in the middle of the year.

Expand

borrowed tranche 2 of loan 1 tranche left and still not close to profitable feel theres gonna be another cap raise soon to pay there debt off while we continue to suffer

No.	Vol.	Price($)
3	91332	6.7¢

No.

Vol.

Price($)

91332

6.7¢

Price($)	Vol.	No.
6.9¢	20001	2

Price($)

Vol.

No.

6.9¢

20001

No.	Vol.	Price($)
2	81332	0.067
1	99587	0.066
2	120000	0.065
2	35341	0.061
1	16588	0.060

No.

Vol.

Price($)

81332

0.067

99587

0.066

120000

0.065

35341

0.061

16588

0.060

Price($)	Vol.	No.
0.069	1	1
0.070	20000	1
0.072	93675	1
0.074	30000	1
0.075	50000	1

Price($)

Vol.

No.

0.069

0.070

20000

0.072

93675

0.074

30000

0.075

50000

(20min delay)
Last 6.9¢		Change 0.000(0.00%)		Mkt cap ! $25.29M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

borrowed tranche 2 of loan 1 tranche left and still not close to...

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Buyers (Bids)

Sellers (Offers)

borrowed tranche 2 of loan 1 tranche left and still not close to...

Top Stories

Bitcoin hits fresh record as instos pile into BTC ETFs – and Trump helps, too

Aussie inflation seemingly hit a 3 year low. So why's the ASX200 red?

Week 44 Wrap: Relatively boring week ahead of US election; HotCopper's most watched; Oz inflation at 3.5%

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Movers and Shakers: Zip Co, MinRes, Kuniko, more – The week's top ASX gainers

Buyers (Bids)

Sellers (Offers)